10x Genomics, Inc.
TXG
Rangering i aksjer
#2167
Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012... Headquartered in Pleasanton, California, 10x Genomics, Inc. (founded in 2012 and known as 10X Technologies, Inc. until November 2014) is a prominent life science technology company. The firm specializes in creating and distributing sophisticated instrumentation, essential consumables, and software designed for in-depth analysis of biological systems. Its market presence extends globally, covering North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company's offerings feature Chromium and Chromium Connect instruments, supported by indispensable items such as microfluidic chips, slides, and reagents. A significant portion of their portfolio focuses on single-cell solutions, leveraging their Chromium platforms. These allow for precise measurement of gene activity at the individual cell level (single cell gene expression), detailed assessment of immune cell function and their targets (single cell immune profiling), exploration of DNA's physical organization and epigenetic modifications (single cell Assay for Transposase Accessible Chromatin - ATAC), and the concurrent quantification of both genetic activity and epigenetic programming across tens of thousands of cells in a single experiment (single cell multiome ATAC + gene expression). Additionally, 10x Genomics offers the Visium spatial gene expression solution, which maps gene activity patterns within specific tissue sections and can also facilitate co-detection of gene expression and proteins when paired with immunofluorescence. Their varied customer base includes academic, governmental, biopharmaceutical, and biotechnology organizations, among others.
Aksjekurs
$72.36
Markedsverdi
$9.43B
Endring (1 dag)
3.53%
Endring (1 år)
450.68%
Land
US
Handel 10x Genomics, Inc. (TXG)
Kategori
Healthcare
P/B-forhold for 10x Genomics, Inc. (TXG)
P/B-forhold per October 2026 TTM: 11.51
Ifølge 10x Genomics, Inc. sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/B-forhold (TTM) 11.51. Ved slutten av 2023 hadde selskapet et P/B-forhold på 8.85.
P/B-historikk for 10x Genomics, Inc. fra 2017 til 2026
P/B-forhold ved hvert års slutt
| År | P/B-forhold | Endre |
|---|---|---|
| 2026 (TTM) | 11.51 | 371.71% |
| 2024 | 2.44 | -72.47% |
| 2023 | 8.85 | 71.82% |
| 2022 | 5.15 | -74.39% |
| 2021 | 20.11 | 3.74% |
| 2020 | 19.38 | 173.32% |
| 2019 | 7.09 | -320.80% |
| 2018 | -3.21 | -40.89% |
| 2017 | -5.43 | 0.00% |
P/B-forhold for lignende selskaper eller konkurrenter
| Selskap | P/B-forhold | Forskjell i P/B-forhold | Land |
|---|---|---|---|
| 2.8261 | -75.45% |
US
|
|
| 37.8989 | 229.28% |
AU
|
|
| 6.3712 | -44.65% |
US
|
|
| 27.6264 | 140.03% |
US
|
|
| - | - |
US
|
